Form 4: Vertex Pharmaceuticals EVP and CMO, Carmen Bozic, Reports Stock Sale
SEC Form 4 Filing
Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, sold 2,280 shares of common stock on July 24, 2024, at a price of $488.46 per share.
Summary
- Carmen Bozic, the Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals, reported a transaction involving the company's common stock.
- On July 24, 2024, Bozic sold 2,280 shares of Vertex Pharmaceuticals common stock at a price of $488.46 per share.
- Following the transaction, Bozic directly owns 25,539 shares of Vertex Pharmaceuticals common stock.
- The sale was executed under a pre-arranged trading plan (Rule 10b5-1) established on February 27, 2024.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to an insider stock sale under a pre-arranged trading plan, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans to sell shares over time.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, but is unlikely to be significant given the pre-planned nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 02/27/2024 | Date of entry into Rule 10b5-1 trading plan |
| 07/24/2024 | Date of stock sale transaction |
| 07/25/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.